Skip to main content
Premium Trial:

Request an Annual Quote

AutoGenomics and Targeted Molecular Dx to Co-Develop Cancer Biomarker Test on Microarray Platform

NEW YORK, July 28 (GenomeWeb News) - AutoGenomics of Carlsbad, Calif., and Targeted Molecular Diagnostics of Westmont, Ill., will co-develop cancer biomarkers for pharmacogenomic tests on a microarray platform, the companies said yesterday.

 

Under the three-year partnership, Targeted Molecular will develop BioFilmChip microarray content, based on its knowledge of signaling pathways, while AutoGenomics will develop the tests on its Infiniti platform.

 

The first test will be a gene expression assay for tumor response and resistance to compounds targeting the HER1 and HER2 pathways. Future assays will cover breast cancer response to therapies, apoptotic response, and resistance to chemotherapy.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.